Join the #tALKpositiveNSCLC Conversation and Pay It Forward

About tALK+

tALK+ (TALK positive) is an initiative that highlights the positive experiences and personal stories of those impacted by non-small cell lung cancer (NSCLC).

Join Takeda Oncology throughout Lung Cancer Awareness Month (November) and on ALK+ Day, November 13, an annual awareness day created to spread awareness and educate about ALK+ NSCLC, including common misconceptions. The goal of tALK+ is to spread positivity throughout the NSCLC community on social media.

Pay it forward by joining the #tALKpositiveNSCLC conversation on social media and sharing positive stories about the NSCLC community. Throughout the month of November, every time the hashtag #tALKpositiveNSCLC is used, Takeda Oncology will make a donation to the Bonnie J. Addario Lung Cancer Foundation.

Use the hashtag #tALKpositiveNSCLC and join the conversation on social media

Follow @TakedaOncology to learn more facts about ALK+ NSCLC

Understanding ALK+ NSCLC and Its Genetic Variations

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of the estimated 222,500 new cases of lung cancer diagnosed each year in the United States, according to the American Cancer Society.

Advancements in scientific research are revealing genetic differences which may explain how lung cancer develops in different types of people—allowing physicians to better understand the various subtypes of NSCLC, and screen for genetic variations present in the cancer at an earlier stage.
Genetic studies indicate that chromosomal rearrangements in the ALK gene are key drivers in a subset of patients with NSCLC.
While the link between lung cancer and smoking is well established, a lack of awareness about other causes of lung cancer has resulted in people with lung cancer feeling blamed for their disease, whether or not they have a history of smoking.

This site is intended for US patients and caregivers only.

You are now leaving Living With ALK.

This link will take you to, a patient registry designed for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Yes, I want to continue No, I want to stay here